Telehealth Alternatives to Zepbound & Mounjaro (2026)
Compare reviewed GLP-1 weight loss providers, billing commitments, and the treatments their links actually offer.
We may earn a commission through provider links. Matching affiliate offers and editorial priorities affect inclusion and suggested order in commercial guides. Scores are not clinical endorsements. Disclosure · Methodology
Compare the options first
Full comparison & price terms ↓A short preview in editorial order—not a guarantee of the cheapest total bill. Read the commitment terms before choosing.
From $49/mo
Lower listed rate · not necessarily monthly billing
Semaglutide $49/mo or tirzepatide $89/mo with 12-month prepayment; $99/$129 month to month.
The Ranking
WellMedr
Compounded GLP-1 care with semaglutide shown at $49/mo or tirzepatide at $89/mo with 12-month prepayment; $99/$129 month to month. Verified affiliate coverage is weight loss only.
Editor’s take: WellMedr is our featured value-led compounded GLP-1 option, not a recommendation for unrelated men's-health or hair-loss treatment. Its public Trustpilot profile displayed 4.6/5 from 1,963 reviews when checked September 27, 2026; customer opinions do not establish clinical effectiveness. Recorded price terms were semaglutide $49/mo or tirzepatide $89/mo with 12-month prepayment; $99/$129 month to month. Compounded medications are not FDA-approved finished drugs. Confirm the exact prescription, pharmacy, dose progression, cancellation terms, and total commitment with the clinician before paying.
Full review →
SkinnyRx
Clinician-guided GLP-1 platform with both compounded and brand-name access plus overnight shipping.
Editor’s take: Premium positioning, premium catalog. If you want maximum optionality across GLP-1 modalities, this is the deepest menu on the site. The premium catalog comes at a premium price. If you want maximum optionality across GLP-1 modalities, SkinnyRx is the deepest menu on the site; if you want the lowest cost, look at Trimi or HealthRx.
Full review →
Direct Meds
Compounded GLP-1 clinic with transparent pricing and dedicated nurse support.
Editor’s take: Direct Meds is easier to compare than a program that separates its membership fee from medication, provided the public $249 and $297 starting points match the treatment path you are offered. Skip it if you specifically want brand-name GLP-1 access or in-state pickup.
Full review →
Shed Rx
GLP-1 clinic offering injections, oral semaglutide, drops, and lozenges plus brand-name Wegovy and Zepbound.
Editor’s take: A reasonable mid-priced pick when delivery flexibility matters. Verify auto-billing terms before signing up given mixed reports. Verify auto-billing terms before signing up given mixed reviews on cancellation. If delivery flexibility is your priority, compare ShedRx against Breeze Meds which also offers sublingual tirzepatide.
Full review →
Women-focused telehealth combining compounded GLP-1 weight loss with HRT support.
Editor’s take: A focused women's health pick. If you only want GLP-1, you'll find cheaper; if you want both GLP-1 and HRT in one clinic, this is one of the cleanest options on the list. If you only want GLP-1 without hormonal support, a lower-cost specialist like Trimi or HealthRx will be more cost-effective. If you want both GLP-1 and HRT in one clinic, Gala Health is one of the cleanest options available.
Full review →
FuturHealth
GLP-1 weight-loss platform combined with personalised nutrition and fitness coaching.
Editor’s take: Coaching is the differentiator. If you're going to use it, FuturHealth pulls ahead of cheaper, drug-only competitors. If you won't, save the money.
Full review →
Flexible, medically guided compounded GLP-1 weight loss with transparent monthly pricing.
Editor’s take: Honest, simple, and focused. No brand-name GLP-1 access is the main trade-off, but for cost-conscious first-time users who just want a guided compounded GLP-1 program without upsells or complexity, that trade-off is rational. Transparent monthly pricing with no hidden fees is a genuine differentiator in a category where pricing opacity is common.
Full review →
Refills
Multi-category telehealth platform covering GLP-1, ED, hair loss, and longevity peptides with no membership fees and flat dosage pricing.
Editor’s take: A versatile multi-category platform with a competitive GLP-1 entry price and no dose-tier price increases. The breadth of treatments (GLP-1, ED, hair, longevity) makes it a practical single-provider option, though the FDA warning letter regarding compounded semaglutide advertising is worth noting.
Full review →2026 Price Comparison. Published Price Terms
Compare the lower and higher listed rates, then read the billing conditions. A listed monthly equivalent may require prepayment; visits, medication, membership, or shipping can cost extra.
Recorded price-check dates: 26 June 2026 – 30 August 2026. Per-provider dates below; these are not a guarantee of today's checkout price.
Rates use different billing terms and are not necessarily all-in or month-to-month. Confirm total charges and cancellation terms. Compounded medications are not FDA-approved finished drugs; pharmacy type alone does not establish legality or clinical suitability.
6 providers · Trustpilot scores are customer opinions, not treatment results.
| Provider & billing terms | Lower listed rate | Higher listed rate | Pharmacy | Reviews & price check | Actions |
|---|---|---|---|---|---|
| WellMedrBest Value Rate Semaglutide $49/mo or tirzepatide $89/mo with 12-month prepayment; $99/$129 month to month. | Lower listed rateFrom $49/mo | Higher listed rate$99 – $129/mo | Pharmacy503A | 4.6/5 1,963 reviews 30 August 2026 | Go WellMedrRead full review |
| SkinnyRxBest Overall Alternative | Lower listed rateFrom $149/mo | Higher listed rateFrom $249/mo | PharmacyBrand + compounded | 4.8/5 5,335 reviews 26 June 2026 | Go SkinnyRxRead full review |
| TrimiLowest Flat Rate Flat rate at every dose | Lower listed rateFrom $99/mo | Higher listed rateFrom $125/mo | PharmacyCompounded 503A | 4.7/5 26 June 2026 | Go TrimiRead full review |
| Shed Rx | Lower listed rateFrom $199/mo | Higher listed rateFrom $449/mo | PharmacyBrand + compounded | 4.7/5 956 reviews 26 June 2026 | Go Shed RxRead full review |
| Found Health | Lower listed rateFrom $129/mo | Higher listed rateFrom $349/mo | PharmacyBrand + compounded | 3.7/5 729 reviews 26 June 2026 | Go FoundRead full review |
| Telos Rx Tirzepatide + oral option | Lower listed rateFrom $99/mo | Higher listed rateFrom $199/mo | PharmacyCompounded 503A | 4.9/5 3 reviews 13 July 2026 | Go Telos RxRead full review |
Provider links may earn a commission. Rate sorting compares the displayed numbers, not equivalent treatment plans or total commitments. How we check price terms →
What to know before choosing
Zepbound and Mounjaro (both tirzepatide) deliver the strongest weight-loss results on the market, but cash-pay pricing of $1,000+ per month, insurance denials, and supply gaps push many people to look for an alternative. This guide is about the switching decision itself: what your realistic options are, what each one costs, and which is the right fit — not just where to buy. Every alternative below routes to a provider we've verified.
Tirzepatide — the molecule in both Zepbound and Mounjaro — produced 20.9% mean weight loss in the SURMOUNT-1 trial (NEJM 2022). The problem is rarely efficacy; it's access. Without insurance, brand-name tirzepatide runs roughly $1,000–$1,300/month, prior authorisations are frequently denied for patients below the BMI threshold, and pharmacy stock has been intermittent.
If you're switching, you have four realistic paths: (1) stay on brand-name tirzepatide but move to a telehealth provider with lower cash pricing or LillyDirect coordination; (2) switch to compounded tirzepatide from a 503A pharmacy under the personalisation exception, typically $99–$299/month; (3) switch molecules to semaglutide (Wegovy/Ozempic or compounded), which is often cheaper and more widely stocked; or (4) move to an oral GLP-1 pill. Each path has a different cost, legal status, and clinical trade-off.
Below we rank the telehealth providers that make each switch realistic, then break down which alternative fits which situation. No provider paid for placement; the ranking reflects our current editorial assessment of price transparency, pharmacy quality, and clinical oversight.
Methodology
We scored each alternative provider on four axes: tirzepatide access (brand-name and/or compounded), price transparency at every dose tier, pharmacy disclosure (503A vs 503B, named partner), and clinical oversight. We then mapped each option to the switching scenario it best solves — cost, insurance denial, supply, or a molecule change. Affiliate-offer eligibility also affects which providers appear and their order, as our methodology explains.
How to Actually Choose a Zepbound or Mounjaro Alternative
Most people don't leave Zepbound or Mounjaro because the drug stopped working — they leave because of cost, an insurance denial, or a stockout at the pharmacy. Each of those reasons points to a different alternative, and choosing the wrong one usually means paying more than you needed to or interrupting a protocol that was working. This section walks through the decision the way we'd talk a friend through it: start from why you're switching, not from a list of brands.
Start With Why You're Switching
There are really only four reasons people switch off brand-name tirzepatide, and they don't lead to the same place. If the issue is cost, the cheapest like-for-like move is compounded tirzepatide from a 503A pharmacy — same molecule, typically $99–$299/month versus $1,000+ for the brand. If the issue is an insurance denial (common below the BMI threshold or without a diabetes diagnosis), the question becomes whether to appeal, switch to a cash-pay telehealth provider, or change molecules entirely. If the issue is supply, switching molecules to semaglutide — which has historically been more reliably stocked — is often the fastest fix. And if the issue is tolerability, a slower titration or a different administration route may matter more than the brand.
The mistake we see most often is treating 'find a cheaper Zepbound' and 'find any effective alternative' as the same search. They aren't. A patient who is doing well on tirzepatide and only needs a lower price should stay on tirzepatide (compounded or a lower cash-pay brand source), not switch to semaglutide and restart titration from zero. A patient who can't reliably get any tirzepatide should be open to switching molecules. Name the constraint first; the alternative falls out of it.
The Insurance Angle Most Pages Ignore
Before you pay cash for any alternative, it's worth understanding why the denial happened, because it changes the math. Commercial plans most often deny obesity-indicated GLP-1s for one of three reasons: the plan excludes weight-loss drugs entirely (an employer formulary choice, not a clinical one), the patient is below the labeled BMI threshold, or a step-therapy requirement hasn't been met. Only the first is truly final — the other two are frequently overturned on appeal with the right documentation.
If your plan excludes weight-loss drugs outright, cash-pay compounded tirzepatide is usually the rational floor on cost, and there's little point spending weeks on an appeal. If you were denied on BMI or step-therapy grounds, an appeal (with documented comorbidities or a prior medication trial) can restore brand-name coverage that's cheaper than any cash-pay option once your copay applies. The providers ranked above that offer brand-name tirzepatide can often coordinate the prior authorization paperwork; the compounded-only providers cannot, because there's nothing for insurance to cover.
What Compounded Tirzepatide Actually Is
Compounded tirzepatide is the same molecule as Zepbound and Mounjaro, prepared by a state-licensed compounding pharmacy rather than manufactured by Eli Lilly. It is not FDA-approved as a finished drug, and its legal availability rests on the 503A personalisation exception, which requires a prescriber to document a specific clinical justification (a customised dose or a documented intolerance to an inactive ingredient, for example). That legal footing is narrower than it was during the 2023–2024 shortage window, and a 2026 FDA proposed rule would further restrict 503B outsourcing-facility compounding of tirzepatide.
The practical implication for a switcher: compounded tirzepatide is a legitimate, much cheaper route today, but it is a less stable long-term supply than the brand. If you choose it, favour clinics that name their pharmacy partner and disclose whether it's a 503A or 503B facility, and have a fallback plan in case the regulatory landscape tightens. Treat the lowest-priced unnamed-pharmacy offers with caution — price-only competition in compounded GLP-1 has attracted operators who obscure their sourcing.
If you take one thing from this section: decide whether your real constraint is price, coverage, supply, or tolerability before you pick an alternative. Each constraint has a different cheapest-correct answer, and the ranking above is sorted to help you act on whichever one applies to you.
What the Studies Actually Show
Zepbound and Mounjaro both contain tirzepatide; the alternatives below are either the same molecule (compounded tirzepatide) or semaglutide (Wegovy/Ozempic and compounded). The figures summarise the pivotal Phase 3 trials for both molecules.
| Endpoint | Finding |
|---|---|
| Mean weight loss (SURMOUNT-1, 72 weeks, 15 mg)1 | −20.9% body weight vs −3.1% placebo in adults with obesity without diabetes |
| Mean weight loss with T2D (SURMOUNT-2, 72 weeks, 15 mg)2 | −14.7% body weight in adults with type 2 diabetes |
| Sleep apnea (SURMOUNT-OSA)3 | Tirzepatide reduced apnea-hypopnea index (AHI) by ~25–29 events/hour vs placebo at 52 weeks; FDA-approved labeling for moderate-to-severe OSA in obesity |
| Mean weight loss (STEP 1, 68 weeks, 2.4 mg)7 | −14.9% body weight vs −2.4% placebo in adults with overweight/obesity without diabetes |
| Cardiovascular outcomes (SELECT, ~40 months)8 | 20% relative risk reduction in major adverse cardiovascular events (MACE) in adults with established CV disease and overweight/obesity |
Frequently Asked Questions
What is the best telehealth alternative to Zepbound?
It depends on why you're switching. If cost is the issue, compounded tirzepatide from a 503A pharmacy ($99–$299/month) is the cheapest like-for-like alternative. If you want to stay on an FDA-approved product, SkinnyRx and Shed Rx offer brand-name Zepbound through licensed clinicians at lower cash-pay rates. If supply or molecule tolerance is the issue, compounded or brand-name semaglutide is a widely available alternative.
Is there a cheaper alternative to Mounjaro?
Yes. The two most common cheaper routes are compounded tirzepatide (same molecule, $99–$299/month under the personalisation exception) and switching to semaglutide (a different GLP-1 that is frequently lower-priced and more reliably stocked). Both are available via telehealth without an in-person visit.
Can I switch from Zepbound to compounded tirzepatide?
In most cases yes, with a prescriber's documented clinical justification (the personalisation exception requires it — for example a customised dose or a documented intolerance to an inactive ingredient). A telehealth clinician can assess whether compounded tirzepatide is appropriate and coordinate the switch. Compounded products are not FDA-approved finished drugs.
Is switching from tirzepatide to semaglutide a downgrade?
Tirzepatide showed larger average weight loss than semaglutide in head-to-head data, but semaglutide is still highly effective (14.9% mean loss in STEP 1) and is often cheaper and more available. For many people the practical access advantage outweighs the efficacy gap. The right choice is individual and should be discussed with a prescriber.
Are compounded tirzepatide alternatives legal in 2026?
503A compounding of tirzepatide remains legal under the personalisation exception, which requires a clinician to document a clinical justification. Note that an FDA proposed rule in 2026 would further restrict 503B outsourcing-facility compounding of tirzepatide. Always confirm your provider's pharmacy licensure and how they document the exception.
- SURMOUNT-1 — NEJM 2022 · Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205–216.
- SURMOUNT-2 — Lancet 2023 · Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2023;402(10402):613–626.
- SURMOUNT-OSA — NEJM 2024 · Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med 2024;391:1193–1205.
- SURPASS — program summary · Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med 2021;385:503–515.
- STEP 1 — NEJM 2021 · Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384:989–1002.
- SELECT — NEJM 2023 · Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023;389:2221–2232.
RxNotebook is an editorial publication, not a medical practice. We are not affiliated with the cited studies; source material does not endorse the providers shown. This is general information, not medical advice.